Actuate says Phase 2 data show elraglusib plus chemo lifts survival in first-line metastatic pancreatic cancer

Actuate

ACTU

0.00

Actuate Therapeutics reported Phase 2 elraglusib data in first-line metastatic pancreatic cancer at the 2026 ASCO Annual Meeting.
Post-hoc analyses indicated longer survival in selected biomarker-defined patients receiving elraglusib with standard chemotherapy versus chemotherapy alone.
A separate Phase 2 study suggested added clinical benefit when elraglusib was combined with FOLFIRINOX, with responses appearing deeper and more durable.
Safety appeared manageable across regimens, supporting further development and potential positioning of elraglusib as a combination backbone therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606010700PRIMZONEFULLFEED9729360) on June 01, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.